ArticleFrontiers in immunology2026
Hearing impairment in patients with axial spondyloarthritis: association with chronic inflammatory burden and neurobiological proteins.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To characterize hearing impairment in patients with axial spondyloarthritis (axSpA) and identify associated clinical and molecular factors. Methods: A cross-sectional study was conducted including 53 patients with axSpA from the REGISPON-3 registry and 17 age- and sex-matched healthy controls (HCs). All participants underwent pure-tone audiometry. Clinical variables included disease duration, structural damage assessed by modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS), inflammatory markers, and persistent inflammation status based on serial C-reactive protein (CRP) measurements during the previous 5 years. Serum proteomic profiling focused on neurobiological pathways was performed. Multivariable regression analyses were adjusted for potential confounding factors. Results: Hearing loss was significantly more frequent in patients with axSpA compared with HCs (86.8%), predominantly bilateral sensorineural hearing loss. Patients with axSpA showed higher hearing thresholds across multiple frequencies, particularly at high frequencies. Axial SpA patients with hearing impairment were older, had longer disease duration, worse ASAS-HI scores, higher structural damage, and greater persistent inflammatory burden in comparison with those without hearing impairment. Mean CRP levels during the previous 5 years were significantly higher in patients with hearing impairment, and the prevalence of hearing loss progressively increased across inflammation persistence groups. Multivariable analyses identified higher circulating levels of HAGH, GDF8, and SPOCK1 as independently associated with hearing impairment after adjustment for structural damage, inflammation, age, sex, disease duration, and NSAID use. Conclusions: Hearing impairment is highly prevalent in axSpA and is associated with cumulative inflammation, structural damage, and an exploratory circulating neurobiological protein profile that requires validation in larger longitudinal studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.